Santen Pharmaceutical Co., Ltd.
3-9-19 Shimo-Shinjo Higashi Yodogawa-ku
Osaka
533
United States
Tel: 81-0-6-3217000
Fax: 81-0-6-3285082
40 articles about Santen Pharmaceutical Co., Ltd.
-
Visiox Pharma Licenses OMLONTI®
7/19/2023
Visiox Pharma, Inc. today announced it has entered into a definitive agreement with Santen Pharmaceutical Co., Ltd to license OMLONTI ®.
-
Santen Agrees to Licensing Agreements and Asset Transfer for its Pharmaceutical Products in North America
7/18/2023
Santen Pharmaceutical Co., Ltd. announced that it has signed licensing agreements and an asset transfer agreement with two U.S. companies.
-
Santen and IAPB Taking Action to Implement the First Ever UN General Assembly Resolution Recognizing the Link Between Eye Health and Sustainable Development
7/26/2021
Santen Pharmaceutical Co., Ltd. announced that Santen, in partnership with the International Agency for the Prevention of Blindness, will take action to implement United Nations General Assembly Resolution A/75/L.108 on eye health.
-
Glaukos Expands its PRESERFLO™ MicroShunt Relationship with Santen via New License Agreement
5/18/2021
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has entered into a new development and commercialization license agreement with Santen Pharmaceutical Co., Ltd. (Santen) for the PRESERFLO™ MicroShunt
-
Santen Announces Health Canada Approval of PRESERFLO MicroShunt
5/4/2021
Santen Canada Inc., a subsidiary of Santen Pharmaceutical Co., Ltd., a global company focused exclusively on ophthalmology, announced the approval of PRESERFLOTM MicroShunt by Health Canada.
-
Santen and Aerie Conclude Exclusive License Agreement for Rhopressa® and Rocklatan® in Japan and Several Other Asian Countries
10/28/2020
Santen Pharmaceutical Co., Ltd. and Aerie Pharmaceuticals, Inc. announced that Santen and Aerie have entered into an exclusive development and commercialization agreement for Rhopressa® and Rocklatan® in Japan, along with rights for several other Asian countries.
-
Santen and U.S. Ophthalmic Company Eyevance Enter into Share Purchase Agreement
9/17/2020
Santen Pharmaceutical Co., Ltd. and Eyevance Holdings LLC announced that Santen Holdings U.S. Inc., a wholly-owned subsidiary of Santen, and Eyevance Holdings LLC entered into a share purchase agreement where Santen Holdings U.S. Inc. acquires all of outstanding shares of Eyevance Pharmaceuticals Holdings Inc..
-
Santen and RVL Pharmaceuticals, Inc., an Osmotica Company, Enter into an Exclusive License Agreement in Japan, Asia, and EMEA for RVL-1201, a First-in-Class Treatment for Acquired Blepharoptosis
7/28/2020
Santen Pharmaceutical Co., Ltd and RVL Pharmaceuticals, Inc., a subsidiary of Osmotica Pharmaceuticals plc, announced an exclusive license agreement covering the development, registration, and commercialization rights in Japan, China, and other Asian countries as well as EMEA countries
-
Santen Announces U.S. FDA Acceptance of Premarket Approval (PMA) Application for DE-128 (MicroShunt) for Review
7/6/2020
Santen Pharmaceutical Co., Ltd. (hereinafter, Santen) today announced that the United States Food and Drug Administration (FDA) has accepted the Premarket Approval (PMA) application for DE-128 (MicroShunt) for review.
-
Santen and Orbis International Join Forces to Expand Access to Training for Eye Care Professionals through Telemedicine Platform
6/18/2020
Santen Pharmaceutical Co., Ltd. and Orbis International announced a partnership to develop a suite of digital training tools that will continue to help eye care professionals around the world build their skills.
-
Santen and TRACON Discontinue Development of DE-122 for Wet Age-Related Macular Degeneration
3/9/2020
Santen Pharmaceutical Co., Ltd. (Head Office: Osaka; hereinafter, “Santen”) and TRACON Pharmaceuticals, Inc. (Head Office: San Diego, CA; hereinafter, “TRACON”) today announced the discontinuation of the development of DE-122 for the treatment of wet age-related macular degeneration (wAMD) following the review of recently obtained top-line data from the Phase 2a AVANTE clinical study. The Phase 2a AVANTE clinical study is a rando
-
Santen to Conduct Activities to Raise Awareness on Importance of Early Detection and Treatment of Glaucoma during World Glaucoma Week (March 8-14, 2020)
3/5/2020
Santen Pharmaceutical Co., Ltd. (Head Office: Osaka; Chairman and CEO: Akira Kurokawa; hereinafter, “Santen”) announced today that it will support glaucoma awareness-raising activities to be conducted around the world from March 8 to 14, 2020.
-
NTC Grants Further License and Distribution Rights to Santen for Its Fixed Combination Dexamethasone With Levofloxacin in South East Asia
5/22/2019
NTC Srl, R&D driven pharmaceutical company with headquarters in Italy, and Santen Pharmaceutical Co. Ltd, a global leader in ophthalmology, announce the extension of their original agreement for Europe signed in December 2017.
-
Santen and Glaukos Enter into Collaboration and Distribution Agreement for Exclusive Distribution of the MicroShunt (DE-128) in the United States
4/26/2019
Santen Pharmaceutical Co., Ltd. and Glaukos Corporation, announced that Santen’s U.S. subsidiary, Santen Inc., has entered into a multi-year agreement whereby Glaukos will become the exclusive distributor of the MicroShunt solely in the U.S. market.
-
Santen to Conduct Activities to Raise Disease Awareness during World Glaucoma Week, March 10 to 16
3/8/2019
Santen Pharmaceutical Co., Ltd. announced on March 8 that as part of its initiatives to increase public awareness of glaucoma, it will sponsor activities to be conducted worldwide during World Glaucoma Week from March 10 to 16, 2019.
-
Santen Receives CRL Letter From FDA for Intravitreal Sirolimus (DE-109)
12/21/2017
The CRL indicates that the FDA is unable to approve the application in its present form and requests additional substantiating evidence to demonstrate efficacy of IVT sirolimus in the treatment of noninfectious uveitis of the posterior segment.
-
Santen Pharma Announces Phase III SAKURA Program Topline Results In Patients With Non-Infectious Uveitis Of The Posterior Segment
11/28/2016
-
Santen Pharma Bags Microshunt Maker InnFocus for $225 Million
7/20/2016
-
TRACON Pharmaceuticals, Inc. Announces IND Filing Of DE-122 (TRC105) For The Treatment Of Wet Age-Related Macular Degeneration By Santen Pharmaceutical
7/1/2015
-
Santen Pharmaceutical Reports Consolidated Performance For The Fiscal Year Ended March 31, 2015
5/12/2015